



0300/BOX/Seq
Page 1 of 1
m

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/978,192	10/15/2001	Avin Ashkenazi	P2630P1C9

CONFIRMATION NO. 3437

FORMALITIES LETTER



OC000000007167479

Ginger R. Dreger, Esq.
Knobbe Martens Olson & Bear
Suite 1150
201 California Street
San Francisco, CA 94111

Date Mailed: 12/07/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT

Case Docket No. GNE. 2630P1C9

Date: January 28, 2002


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ashkenazi et al.
Appl. No. : 09/978,192
Filed : October 15, 2001
For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND
NUCLEIC ACIDS
ENCODING THE SAME
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in an
envelope addressed to: Commissioner for Patents,
Washington, D.C. 20231, on

January 28, 2002

(Date)


Ginger R. Dreger, Reg. No. 33,055

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231


Dear Sir:

Enclosed for filing in the above-identified application is the following:

- (X) Amendment;
- (X) Sequence Submission Statement;
- (X) Substitute Sequence Listing;
- (X) Substitute Sequence Listing in computer readable form;
- (X) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410; and

- (X) A return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ashkenazi et al.

Appl. No. 09/978,192

Filed : October 15, 2001

For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME

Examiner : Unknown

) Group Art Unit Unknown

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first-class mail in
) an envelope addressed to: Commissioner for
) Patents, Washington, D.C. 20231, on

January 28, 2002

(Date)

Ginger R. Dreger, Reg. No. 33,055

SEQUENCE SUBMISSION STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed December 7, 2001. I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a) and included in the Substitute Sequence Listing submitted herewith, are supported in the application, and that the Substitute Sequence Listing does not include new matter.

I further state that the information recorded in the currently submitted substitute copy of the computer-readable form of the Sequence Listing is identical to the paper form of the Sequence Listing submitted herewith as required in 37 C.F.R. § 1.825(b).

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 28, 2002

By: 

Ginger R. Dreger

Registration No. 33,055

Attorney of Record

620 Newport Center Drive, 16th Floor

Newport Beach, CA 92660

(415) 954-4114